Zhang Ya, Ma WenHao, Li Ning, Yang Mei, Hou Changjun, Huo Danqun
Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing 400044, PR China.
National Facility for Translational Medicine, Shanghai Jiao Tong University, Shanghai 200240, PR China.
Anal Chem. 2024 Aug 15. doi: 10.1021/acs.analchem.4c01877.
Simultaneous detection of multiple tumor markers is of great significance for an accurate diagnosis and early treatment of cancer. Electrochemical homogeneous biosensing strategies have been shown to have advantages, such as high sensitivity and no electrode modification, but they are still a challenge in the field of simultaneous detection of multiple tumor markers. The ER, PR, HER2, and Ki67 proteins are the standard biomarkers for the clinical molecular typing of breast cancer. Precise, sensitive, and simultaneous detection of these four biomarkers is of great importance in the molecular typing of breast cancer, which helps in the creation of personalized treatment plans. In the present study, we developed an electrochemical homogeneous electrochemical bioplatform based on metal ions/SiONPs/magnetic beads for detection of the four biomarkers and simultaneous diagnosis of the 10 types of breast cancer directly in human serum at one system by a single electrode. The electrochemical bioplatform has a short detection time of 140 min; however, the current clinical tissue testing time takes about 1 week. Also, the electrochemical bioplatform selectively detects HER2, ER, Ki67, and PR in a range of 0-1000 pg/mL with detection limits of 2, 1.8, 10.36, and 1.33 pg/mL, respectively.
同时检测多种肿瘤标志物对于癌症的准确诊断和早期治疗具有重要意义。电化学均相生物传感策略已显示出具有高灵敏度和无需电极修饰等优点，但在同时检测多种肿瘤标志物领域仍是一项挑战。雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2（HER2）和Ki67蛋白是乳腺癌临床分子分型的标准生物标志物。精确、灵敏且同时检测这四种生物标志物在乳腺癌分子分型中至关重要，有助于制定个性化治疗方案。在本研究中，我们开发了一种基于金属离子/二氧化硅纳米粒子/磁珠的电化学均相电化学生物平台，用于在一个系统中通过单个电极直接检测人血清中的这四种生物标志物并同时诊断10种类型的乳腺癌。该电化学生物平台检测时间短，仅需140分钟；然而，目前临床组织检测时间约为1周。此外，该电化学生物平台能在0 - 1000 pg/mL范围内选择性检测HER2、ER、Ki67和PR，检测限分别为2、1.8、10.36和1.33 pg/mL。
